Can a Triple-Drug attack stop eye lymphoma in its tracks?
NCT ID NCT06973811
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This phase II trial is testing a combination of three drugs—zanubrutinib, rituximab, and methotrexate—given through the vein and directly into the eye, for people newly diagnosed with primary intraocular lymphoma, a rare cancer of the eye. The goal is to see if this regimen can improve the time patients live without the cancer progressing. Participants will receive the treatment over several months, followed by a maintenance phase with zanubrutinib alone for up to two years.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of zanubrutinib (oral), rituximab (IV), and methotrexate (IV and intravitreal injections)
- What this could lead to
- If successful, this combination could offer a more effective first-line treatment for primary intraocular lymphoma, potentially delaying or preventing relapse and preserving vision.
- What could go wrong
- This is a phase II trial with a small number of participants, so results may not be conclusive. The treatment involves high-dose chemotherapy and eye injections, which carry risks like infection, bleeding, or damage to the eye, and may not be tolerated by all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY INTRAOCULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking Union Medical College Hospital
RECRUITINGBeijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.